Recombinant human interleukin-2（Jiangsu Kingsley)

重组人白介素-2 (江苏金丝利）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2（Jiangsu Kingsley)
Drug Alias Name注射用重组人白介素-2（江苏金丝利）重组人白细胞介素-2（江苏金丝利）因特康
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsPleural Effusion, MalignantCarcinoma, Renal CellMelanoma
Global Approved IndicationsPleural Effusion, MalignantCarcinoma, Renal CellMelanoma
Approved Indications in ChinaPleural Effusion, MalignantCarcinoma, Renal CellMelanoma
Original Approved Country/TerritoryMainland China
Original Approved Date1997/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Kingsley Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Kingsley Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPleural Effusion, MalignantCarcinoma, Renal CellMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A